New Zealand Multiple Sclerosis (MS)

Asia Pacific Multiple Sclerosis Drugs Market, By Disease Type (Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Severe Relapsing-Remitting Multiple Sclerosis (RES)); By Treatment (Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, Symptomatic Therapies); By Drug Type (Branded, Generic); By End User (Hospital & Clinics, Diagnostic Laboratories); By Country (China, India, Japan, South Korea, Australia & New Zealand, Indonesia, Malaysia, Singapore, Vietnam, Rest of APAC), Competitive Landscape & Forecast, 2019–2029

Nov 10, 2023  |  Published by: BlueWeave Consulting  |  USD 3,599

... End User (Pharmaceutical & Biopharmaceutical Companies, Labs & Research Institutes, Healthcare Providers, Healthcare Payers); By Application (Drug Discovery & Development, Medical Diagnostics, Genomics & Precision Medicine, Radiotherapy, Risk Analysis); By Region (North America, Europe, Asia ... Read More